Intellia begins rolling FDA submission for gene editing therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid'
April 27, 2026 10:48 AM EDTTD Cowen analyst Joseph Thome reiterated a Buy rating on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "NTLA released Ph. III data of its in vivo gene editing candidate lonvo-z for the treatment of HAE this morning. The trial hit both primary and... More
